Barnes P J
Department of Thoracic Medicine, National Heart and Lung Institute, Brompton Hospital, London, England.
Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S70-6.
Bronchial hyperresponsiveness (BHR) and asthma symptoms are linked to chronic inflammation in the airway. Corticosteroids reduce BHR and asthma symptoms and, although their precise mode of action is not yet certain, it is likely that they suppress the allergic inflammatory response. They may act on macrophages, eosinophils, lymphocytes, and airway microvascular leak to inhibit the late response and BHR that follows allergen exposure, whereas chronic administration may also reduce the number of mast cells in airways to decrease the immediate response to allergen and exercise. In view of the safety of administration, inhaled corticosteroids should be considered as first line therapy for chronic asthma, with the aim of suppressing inflammation and reducing the need for bronchodilator therapy.
支气管高反应性(BHR)和哮喘症状与气道慢性炎症有关。皮质类固醇可降低BHR和哮喘症状,尽管其确切作用方式尚不确定,但它们可能会抑制过敏性炎症反应。它们可能作用于巨噬细胞、嗜酸性粒细胞、淋巴细胞和气道微血管渗漏,以抑制过敏原暴露后的迟发性反应和BHR,而长期给药也可能减少气道中肥大细胞的数量,从而降低对过敏原和运动的即时反应。鉴于给药的安全性,吸入性皮质类固醇应被视为慢性哮喘的一线治疗药物,旨在抑制炎症并减少支气管扩张剂治疗的需求。